GT Biopharma Inc stock (US36254L1098): FDA clears IND for NK cell therapy GTB-5550 in solid tumors

GT Biopharma Inc (GTBP) has announced that the U.S. Food and Drug Administration has cleared an Investigational New Drug (IND) application for GTB?5550, a B7?H3?targeted natural killer (NK) cell engager, paving the way for a first?in?human clinical trial in patients with advanced solid tumors, according to a company press release dated April 29, 2026 and posted on its investor relations site.GT Biopharma IR as of 04/29/2026

The IND clearance follows prior FDA authorization for GTB?5550 in pediatric solid tumors and marks a key regulatory milestone for GT Biopharma’s TriKE® platform, which is designed to engage CD16 on NK cells while delivering an IL?15 moiety to enhance anti?tumor activity.GT Biopharma IR as of 04/29/2026

As of: 08.05.2026

By the editorial team – specialized in equity coverage.

GT Biopharma Inc: core business model

GT Biopharma Inc is a clinical?stage biopharmaceutical company focused on developing and commercializing immuno?oncology products that harness natural killer (NK) cells to target cancer.GT Biopharma IR as of 05/08/2026

The company’s proprietary TriKE® platform links a tumor?targeting antibody fragment with an IL?15 cytokine moiety, aiming to direct NK cells to specific antigens on cancer cells while providing sustained activation and survival signals.GT Biopharma product pipeline as of 05/08/2026

GT Biopharma’s strategy centers on advancing multiple TriKE candidates through early?phase trials in hematologic malignancies and solid tumors, with the goal of generating clinical data that can support partnerships, licensing deals, or later?stage development funding.GT Biopharma IR as of 04/29/2026

Main revenue and product drivers for GT Biopharma Inc

GT Biopharma’s primary value drivers are its clinical?stage NK cell engagers, particularly GTB?3650 and GTB?5550, which are being evaluated in relapsed or refractory hematologic malignancies and solid tumors, respectively.GT Biopharma IR as of 04/29/2026

GTB?3650, a CD33?targeted TriKE, has reported successful Phase 1 trial progress in patients with relapsed or refractory CD33?expressing hematologic cancers, according to a recent update cited by financial news outlets.MarketBeat GTBP news as of 10/08/2025

GTB?5550, the newly IND?cleared B7?H3?targeted TriKE, is intended for advanced solid tumors and pediatric solid tumors, broadening GT Biopharma’s potential addressable market beyond blood cancers into areas such as sarcomas and other B7?H3–expressing malignancies.GT Biopharma IR as of 04/29/2026

For U.S. investors, GT Biopharma’s Nasdaq listing and U.S.?based development activities mean that regulatory decisions from the FDA, clinical trial readouts, and potential partnership announcements are likely to be key price catalysts for GTBP shares.StockAnalysis GTBP overview as of 05/08/2026

Conclusion

GT Biopharma Inc’s FDA clearance of the IND for GTB?5550 represents a meaningful step in expanding its TriKE platform into solid tumors, a large and underserved oncology segment.GT Biopharma IR as of 04/29/2026

However, as a clinical?stage biotech with no commercial products, the company remains highly dependent on trial outcomes, regulatory decisions, and its ability to secure funding or partnerships, which can lead to significant stock?price volatility.StockAnalysis GTBP overview as of 05/08/2026

For U.S. investors, GT Biopharma Inc offers exposure to an emerging NK cell?based immuno?oncology approach, but the profile is suited mainly to those comfortable with high?risk, high?uncertainty biotech investments rather than conservative or income?oriented portfolios.GT Biopharma product pipeline as of 05/08/2026

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.